Teaching the body
to fight cancer again.
NOVEL ONCOLYTIC IMMUNOTHERAPY
Tychon Biosciences is advancing precision cancer immunotherapy through a novel approach that transforms a patient’s immune cells into a “PAR-T” cell trained to find and eliminate cancer cells.
Despite its promise as a new cancer treatment, clinical adoption of T-cell based immunotherapy has been slow due to a variety of shortcomings. Our therapy delivers on this promise by addressing these shortcomings with a novel approach.
Our PAR-T technology can be used as a primary therapy or in combination with other therapies, opening up enormous untapped potential to treat early and late-stage cancers.
Introducing: TYC201
A protein-based drug that activates your T-cells to find and eliminate cancer.
Tychon Highlights
Safer
MINIMAL CYTOKINE ACTIVATION
FASTER
OFF-THE-SHELF THERAPY
CHEAPER
STANDARD PROTEIN MANUFACTURING
PATIENT FRIENDLY
WEEKLY DOSING
CONTROLLABLE
THERAPY CAN BE “TURNED OFF” WITH COMMON ANTIBIOTIC